SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

TGTX

TG Therapeutics, Inc.
NASDAQHealth Care

Latest close: 53.97 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Sep 10, 2026Reported sale · Form 4Laurence N Charney · $274.8KOpen the filing ↗
  2. Sep 10, 2026Notice of sale · Form 144Charney Laurence N · Director · $274.8KOpen the filing ↗
  3. Aug 5, 2026Quarterly report · 10-QFiled by the company itself.Open the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record96911 flagged findings
Reported transactions (Form 4)45since Jan 5, 2024
Corporate events (8-K)30since Jun 12, 2014

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

What the company does

a commercial stage biopharmaceutical company

Source: Wikidata (CC0 1.0) · copied on Sep 3, 2026 · may not reflect recent changes.

SEC topics

Regulatory history

Topics detected in its SEC reports, with the original excerpt.

Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.

  • 2026-05-06share offering or dilution eventrecentOpen filing ↗
    “…Payment and are collectively known as the Precision Shares. All Precision Shares are recognized at fair market value as of March…”
    +1 more passage from the same document
    • “…Precision Shares. All Precision Shares are recognized at fair market value as of March 31, 2026, and are classified as an equity…”
  • 2026-05-06capital return (buybacks/dividends)recentOpen filing ↗
    “…B. Riley Securities, Inc. has expired. The Company may offer and sell securities registered under the 2025 WKSI Shelf in one or…”
    +1 more passage from the same document
    • “…in one or more offerings, from time to time, depending on market conditions and its capital needs. The Company may also file…”
  • 2026-05-06regulatory investigationrecentOpen filing ↗
    “…that we or our subsidiaries submit; ● recalls; ● suspension or termination of ongoing clinical trials; ● fines, restitutions, or…”
  • 2026-05-06Department of Justice inquiryrecentOpen filing ↗
    “…services to help patients access the product. Our patient support programs are administered in conjunction with a patient…”
  • 2026-05-06reverse splitrecentOpen filing ↗
    “…Upfront Precision Stock Payment), as an equity investment, for the purchase of 2,920,816 shares of Precision’s common stock at a…”

Original excerpts from SEC filings, untranslated. Not advice and not a prediction.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 969)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Sep 14, 26Form 4 ↗Insider transaction
  • Sep 10, 26Form 144 ↗Notice of proposed sale
  • Aug 7, 26Form 4 ↗Insider transaction
  • Aug 5, 2610-Q ↗Quarterly report
  • Aug 3, 268-K ↗Current report · Results
  • Insider transaction · 5 Form 4 filingsshow all 5hide
  • Jun 12, 268-K ↗Current report · Shareholder vote results
  • Jun 3, 268-K ↗Current report · Other events
  • May 27, 268-K ↗Current report · Other events
  • May 6, 2610-Q ↗Quarterly report
  • May 6, 268-K ↗Current report · Results
  • Apr 30, 26DEF 14A ↗Shareholder meeting and votes
  • Apr 29, 26SCHEDULE 13G ↗Passive stake · Vanguard Portfolio Management · 5.3% · event on Mar 31, 26
  • Mar 27, 26SCHEDULE 13G/A ↗Passive stake · amendment
  • Mar 20, 268-K ↗Current report · Entered a material agreement
  • Feb 27, 2610-K ↗Annual report
  • Feb 26, 268-K ↗Current report · Results
  • Jan 29, 26Form 4 ↗Insider transaction
  • Jan 13, 268-K ↗Current report · Communication to the market
  • Insider transaction · 2 Form 4 filingsshow all 2hide

969 filings on record, the oldest from Aug 30, 96.

Listing the 25 most recent filings of the 969 on record.

8-Ks, explained

Stress5Structure70Governance33
  • Mar 20, 26StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Aug 6, 24StructureEntered a material agreement+4 more in the same filing8-K 1.01 ↗
  • Jun 17, 24GovernanceA senior executive left or was appointed+3 more in the same filing8-K 5.02 ↗
  • Structure3 material agreements entered2022 – 2024show all 3hide
    • Jan 10, 24StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
    • Aug 1, 23StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
    • Jan 4, 22StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Jun 23, 21GovernanceA senior executive left or was appointed8-K 5.02 ↗
  • Apr 13, 21GovernanceAuditor change filing (8-K Item 4.01)+1 more in the same filing8-K 4.01 ↗
  • Dec 16, 20StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Jun 24, 20GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • May 18, 20StructureEntered a material agreement+1 more in the same filing8-K 1.01 ↗
  • Apr 30, 20GovernanceA senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
  • Structure4 material agreements entered2017 – 2019show all 4hide
    • Mar 5, 19StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
    • Jun 20, 18StructureEntered a material agreement8-K 1.01 ↗
    • Jan 8, 18StructureEntered a material agreement8-K 1.01 ↗
    • Mar 9, 17StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Jan 4, 17GovernanceA senior executive left or was appointed8-K 5.02 ↗

11 older filings not shown · The record reaches back to Jan 6, 05.

Notable in the record

Stress disclosures older than the timeline above. They are individual events from the record, not a complete timeline: there may be more between them.

  • Feb 28, 08StressListing notice (8-K 3.01)+2 more in the same filing8-K 3.01 ↗
  • Sep 21, 07StressListing notice (8-K 3.01)+1 more in the same filing8-K 3.01 ↗
  • Mar 30, 07StressListing notice (8-K 3.01)+1 more in the same filing8-K 3.01 ↗
  • Jan 12, 07StressListing notice (8-K 3.01)+1 more in the same filing8-K 3.01 ↗
  • Aug 14, 06StressPast accounts declared unreliable and being restated8-K 4.02 ↗

The full record holds 5 stress filings.

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

Sale intention announced

On Sep 10, Charney Laurence N filed notice of intent to sell up to $275K.

A notice is not a sale: it may not go ahead, may happen in part, or at a different price.

After the notice, they sold $275K on Sep 10, per their Form 4. That is 100% of the shares announced so far, and the window is still open.

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Sep 10, 26Sell$275KLaurence N Charney↗
  • Nov 24, 25Sell$163KYann Echelard↗
  • Sep 11, 25Sell$672KSagar Lonial↗
  • Jun 13, 25Sell$369KYann Echelard↗
  • Jan 6, 25Sell$286KSean A PowerCFO↗
  • Jan 3, 25Sell$343KSean A PowerCFO↗
  • Nov 11, 24Sell$755KLaurence N Charney↗
  • Nov 11, 24Sell$152KSagar Lonial↗
  • Nov 5, 24Sell$490KYann Echelard↗
  • Jun 20, 24Sell$276KSagar Lonial↗
  • Jun 17, 24Sell$157KSagar Lonial↗
  • Mar 13, 24Sell$80KSagar Lonial↗

There are 2 more transactions in this stretch.

Stock compensation, tax and giftsshow the 26 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Aug 7, 26Giftamount n/aLaurence N Charney↗
  • Aug 7, 26Giftamount n/aLaurence N Charney↗
  • Aug 6, 26Giftamount n/aLaurence N Charney↗
  • Jan 29, 26Giftamount n/aLaurence N Charney↗
  • Jan 28, 26Giftamount n/aLaurence N Charney↗
  • Jan 8, 26Compensationamount n/aSean A PowerCFO↗
  • Jan 8, 26Compensationamount n/aMICHAEL S WEISSCEO↗
  • Nov 5, 25Giftamount n/aMICHAEL S WEISSCEO↗
  • Nov 5, 25Giftamount n/aMICHAEL S WEISSCEO↗
  • Jun 12, 25Compensationamount n/aSagar Lonial↗
  • Jun 12, 25Compensationamount n/aDANIEL HUME↗
  • Jun 12, 25Compensationamount n/aKenneth Hoberman↗
  • Jun 12, 25Compensationamount n/aLaurence N Charney↗
  • Jun 12, 25Compensationamount n/aYann Echelard↗
  • Mar 17, 25Giftamount n/aDANIEL HUME↗
  • Mar 10, 25Giftamount n/aLaurence N Charney↗
  • Jan 29, 25Compensationamount n/aSean A PowerCFO↗
  • Jan 29, 25Compensationamount n/aMICHAEL S WEISSCEO↗
  • Nov 12, 24Giftamount n/aLaurence N Charney↗
  • Jun 19, 24Compensationamount n/aLaurence N Charney↗
  • Jun 19, 24Compensationamount n/aYann Echelard↗
  • Jun 19, 24Compensationamount n/aKenneth Hoberman↗
  • Jun 19, 24Compensationamount n/aDANIEL HUME↗
  • Jun 19, 24Compensationamount n/aSagar Lonial↗
  • Jan 6, 24Compensationamount n/aMICHAEL S WEISSCEO↗
  • Jan 5, 24Compensationamount n/aSean A PowerCFO↗

The full record holds 54 transactions and goes back to Jan 4, 23.

Its sector and its market

TG Therapeutics, Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From TG Therapeutics, Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow TG Therapeutics, Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
250 clean closes in the period.
SEC records
969 documents on file, from Aug 30, 1996 to Sep 14, 2026.
Company description
Wikidata, read on Sep 3, 2026.
This page
Generated on Oct 19, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.